EWING, NJ--(Marketwire - November 14, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) (DOR or the Company), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, today announced its financial results for the third quarter ended September 30, 2008
